SOURCES SOUGHT
B -- Testing Services for Lead Compounds for Additional Characterization and Reagent - List of GPCR Targets
- Notice Date
- 5/28/2015
- Notice Type
- Sources Sought
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-SBSS-2015-392
- Archive Date
- 6/20/2015
- Point of Contact
- Samantha A. Kelly, Phone: 3014028855
- E-Mail Address
-
samantha.kelly2@nih.gov
(samantha.kelly2@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- List of Kinase Targets referenced in the sources sought notice. List of GPCR Targets referenced in the sources sought notice. SOURCES SOUGHT NOTICE TEMPLATE 1.Solicitation Number:HHS-NIH-NIDA-SSSA-SBSS-2015-392 2.Title: Testing Services for Lead Compounds for Additional Characterization and Reagent 3.NAICS Code: 541380 - Testing Laboratories 4.Description: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The NCATS Chemical Genomics Center (NCGC) is tasked with identifying and developing novel small molecule leads against a wide spectrum of human disease targets, which it accomplishes by screening thousands of small molecules in collaboration with both intra-and extramural researchers. A In pursuit of this goal, the Center has a strong internal transdisciplinary team of scientists who continually discover novel small molecules for application against a wide range of human diseases. As such, NCATS routinely acquires fee-for-service analytical tests to better characterize lead molecules. Each of these profiling services has different objectives. The kinase assay panel is required to assess NCATS synthesized small molecules against a large number of kinases that include clinical relevant mutants, lipid, atypical and pathogen kinases in order to annotate our compounds with this type of information. In order to better understand the biology of a small molecule in biological systems, it is important to establish selectivity of the compound. This annotation and characterization is extremely helpful in further understanding the biology, will help decide next steps, and data could be used in publications. G protein-coupled receptors (GPCRs), constitute a large protein family of receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. When a ligand binds to the GPCR it causes a conformational change in the GPCR, which allows it to act as a guanine nucleotide exchange factor (GEF). The GPCR can then activate an associated G-protein by exchanging its bound GDP for a GTP. The G-protein's α subunit, together with the bound GTP, can then dissociate from the β and γ subunits to further affect intracellular signaling proteins or target functional proteins directly depending on the α subunit type (Gαs, Gαi/o, Gαq/11, Gα12/13). GPCRs are involved in a wide variety of physiological processes, such as our senses (visual, gustatory, olfactory), mood regulation, immune system activity, nervous system transmission, cell density sense, homeostasis modulation, tumor growth and metastasis, to name a few. Generally, GPCRs are activated by an external signal in the form of a ligand or other signal mediator. This creates a conformational change in the receptor, causing activation of a G protein. Further effect depends on the type of G protein. Given their great importance and involvement in many of the body's processes, GPCR panels are frequently run as part of the drug discovery process to better understand the activity and selectivity of a small molecule against a large panel of various GPCRs. This critical information is needed for 10 of our small molecules that were developed by NCATS. NCATS is also interested to assess small molecule in a comprehensive platform that allows to provide physiologically relevant insights about a compound prior to lengthy and expensive animal or clinical studies. As such, NCATS requires that small molecules will be tested in controlled sets of human primary cell cultures and co-cultures that are primed to physiologically model human disease states. The responses need to be measured and recorder and the activity profile of the compound should be compared to a large number of reference profile provided by the vendor that is generated from well characterized pharmalogical agents. The results that NCATS will obtain, will inform the next steps in development, providing clinically relevant predictions about the molecular target, mechanism of action, off-target effects, toxicity, potency, pharmacodynamic properties, and biomarkers for NCATS compounds. This platform shall include a tox panel, an oncology panel, and a diversity panel that represent a broad range of human biology relevant to multiple therapeutic areas. Furthermore, NCATS is also in need of a reagent, the PathHunter Detection Kit (or brand name equal). Purpose and Objectives: The purpose of this acquisition is to purchase analytical testing services that support NCATS projects and reagents. Requirements: Comprehensive Physiological Profiling •Vendor shall assess small molecules in a comprehensive profiling platform for the purpose of understanding the biological action of the compound in primary human cell-based systems. •Vendor shall assess 10 compound per each specific platform in 4 concentrations, these platforms include a diversity platform (1 replicate), toxicology platform (1 replicate), and an oncology platform (3 replicates). •Vendor shall provide a study report within 10 weeks with annotations of activities with respect to biological significance and results of mechanism prediction. GPCR Profiling •Vendor shall assess small molecules in a GPCR panel. •Vendor shall provide over 400 targets in panel, screen a total of 10 compounds, and provide 8180 data points in final report. •Vendor shall be able to screen at least 95% of the targets listed in "List of GPCR targets" and list all target available. •Vendor shall assess small molecule in 1 concentration in duplicate. •Vendor shall provide study report within 5 weeks that indicates activity against each target as listed in "List of GPCR targets" Kinase Profiling •Vendor shall assess 10 small molecules in a kinase panel. •Vendor shall provide a kinase panel that comprises 468 targets. •Vendor shall be able to screen at least 95% of the targets listed in "List of kinase targets" and list all target available. •Vendor shall assess each small molecule in 1 concentration in duplicate. •Vendor shall provide study report within 3 weeks that indicate activity against each target listed in "List of kinase targets" PathHunter (or brand name equal) Detection Kit •Vendor shall provide an assay kit that allows for enzyme fragment complement detection. •Vendor shall provide a ready to use kit that requires one-step addition, in compatible with 1536, 384, and 96 well formats, and can be detected on a luminometer. •Vendor shall deliver reagent within 6 weeks from award date. Deliverable/Reporting Requirements: TypeDelivery time frame (weeks)Requirements Comprehensive Physiological Profiling10Report detailing annotations of activities with respect to biological significance and results of mechanism prediction GPCR Profiling5Study report indicating activity against each target as listed in "List of GPCR targets" Kinase Profiling3Study report indicating activity against each target as listed in "List of kinase targets" PathHunter Detection Kit6N/A Capability statement /information sought. Contractors that believe they possess the ability to provide the requirement should submit documentation of their ability to meet each of the project requirements to the Contract Specialist. The response should directly and specifically state in the, capabilities statement, which project requirements you can supply. Contractors must also provide their Company Name, DUNS Number, Physical Address, Point of Contact, and Size and Type of Business (e.g., 8(a), HubZone, etc.) pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The information submitted must be must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses (capability statements) sent in response to this Small Business Sources Sought Notice must be submitted electronically (via e-mail) to the Contract Specialist. Facsimile responses are NOT accepted. The response must be submitted to Samantha Kelly, Contract Specialist at e-mail address Samantha.Kelly2@nih.gov The response must be received on or before June 5, 2015 at 12:00PM, eastern time. "Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-SBSS-2015-392/listing.html)
- Record
- SN03746335-W 20150530/150529040731-63db7cd41606c920fa4b227f0de007a8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |